

RESEARCH

Open Access

The diminishing returns of atovaquone-proguanil for elimination of *Plasmodium falciparum* malaria: modelling mass drug administration and treatment

Richard J Maude^{1,2*}, Chea Nguon³, Arjen M Dondorp^{1,2}, Lisa J White^{1,2} and Nicholas J White^{1,2}

Abstract

Background: Artemisinin resistance is a major threat to current efforts to eliminate *Plasmodium falciparum* malaria which rely heavily on the continuing efficacy of artemisinin combination therapy (ACT). It has been suggested that ACT should not be used in mass drug administration (MDA) in areas where artemisinin-resistant *P. falciparum* is prevalent, and that atovaquone-proguanil (A-P) might be a preferable alternative. However, a single point mutation in the cytochrome b gene confers high level resistance to atovaquone, and such mutant parasites arise frequently during treatment making A-P a vulnerable tool for elimination.

Methods: A deterministic, population level, mathematical model was developed based on data from Cambodia to explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperazine ACT for mass drug administration and/or treatment of *P. falciparum* malaria, with and without adjunctive primaquine (PQ) and long-lasting insecticide-treated bed nets (LLIN). The aim was local elimination.

Results: The model showed the initial efficacy of ACT and A-P for MDA to be similar. However, each round of A-P MDA resulted in rapid acquisition and spread of atovaquone resistance. Even a single round of MDA could compromise efficacy sufficient to preclude its use for treatment or prophylaxis. A switch to A-P for treatment of symptomatic episodes resulted in a complete loss of efficacy in the population within four to five years of its introduction. The impact of MDA was temporary and a combination of maintained high coverage with ACT treatment for symptomatic individuals and LLIN was necessary for elimination.

Conclusion: For malaria elimination, A-P for MDA or treatment of symptomatic cases should be avoided. A combined strategy of high coverage with ACT for treatment of symptomatic episodes, LLIN and ACT + P MDA would be preferable.

Keywords: Mathematical, Model, Falciparum, Malaria, Atovaquone, Artemisinin, Dihydroartemisinin, Resistance

Background

Efforts are underway to eliminate *Plasmodium falciparum* malaria in many malaria-endemic countries [1]. A major threat to these efforts is the recent identification of artemisinin resistance in Cambodia [2], Thailand [3], Myanmar [4], and Vietnam [5]. Artemisinin combination

therapy (ACT) is first-line treatment for malaria worldwide and thus an important component of strategies for malaria elimination.

Mathematical modelling predicts that by using ACT at high coverage, as part of a combined strategy, artemisinin-resistant malaria can be eliminated. To do so would require elimination of all malaria in an area as the last few infections to be cleared are most likely to be resistant [6]. Atovaquone-proguanil (A-P) has been proposed as an alternative anti-malarial to ACT to reduce selective pressure for the spread of artemisinin resistance, and

* Correspondence: richardmaude@gmail.com

¹Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

²Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Old Road, Oxford OX3 7LJ, UK

Full list of author information is available at the end of the article

has been deployed as first-line treatment in western Cambodia and adjacent parts of Thailand. A-P is also being considered as a candidate for mass drug administration (MDA), rather than treatment, in Cambodia [7]. Using A-P for MDA in the presence of artemisinin resistance has the advantage of not adding additional artemisinin drug pressure on the parasite population. A major drawback of A-P is the frequent emergence of mutations conferring high level atovaquone resistance, rendering the drug dangerously ineffective [8]. A single point mutation in the cytochrome b (*cyt b*) gene, which occurs at a viable frequency around $1:10^{12}$ parasites, encodes high-level resistance.

A mathematical model was developed to explore the possible effects of large-scale use of A-P compared to dihydroartemisinin-piperaquine ACT for MDA and/or treatment of *P. falciparum* malaria, with and without adjunctive primaquine (PQ) and long-lasting insecticide-treated bed nets (LLIN), with the aim of local elimination.

Methods

A deterministic, population level, mathematical model of *P. falciparum* malaria transmission and treatment in low transmission settings was developed. It was based on a previously published modelling framework for elimination of artemisinin-resistant *P. falciparum* malaria in Cambodia [9] and was solved numerically using Berkeley Madonna™ (CA, USA). The model includes the effects of anti-malarial treatment at different stages of the parasite life cycle, atovaquone and artemisinin resistance, seasonally varying transmission intensity, symptomatic and asymptomatic infections and immunity. The updated model structure is shown diagrammatically in Figure 1. Model assumptions are listed in Additional file 1: Table S1, the parameter values and their sources in Additional file 2: Table S2. Treatment and MDA in the model were with either three days of once daily dihydroartemisinin-piperaquine (referred to as 'ACT' throughout the text) or three days of once daily A-P. The model was designed to predict the efficacy of interventions in low transmission settings.

Western Cambodia was considered in detail as a case study for elimination of artemisinin-resistant malaria but the findings are generalizable to any low transmission setting with a median multiplicity of infection of 1 and seasonal variation in transmission intensity. There have been various estimates of parasite prevalence (proportion of population with parasites of any stage in the peripheral blood) in parts of Cambodia using microscopy, spleen rates and polymerase chain reaction. In the absence of a consensus for western Cambodia, in the model this was set at a mean of 15%. To approximate the seasonal variation in parasite prevalence in western

Cambodia, the model was fitted using the least squares method to national malaria surveillance data from the Cambodia National Malaria Control Programme, as described elsewhere [9]. These data and derived estimates of total malaria burden over time in Cambodia will be published separately. The proportion of infections that were artemisinin-resistant in 2013 in western Cambodia was unknown, although studies are underway in some areas that will provide estimates of this. In the model, in western Cambodia 10% of infections were assumed to be artemisinin resistant. Atovaquone resistance was assumed to be absent prior to the introduction of A-P and a fitness cost of atovaquone resistance was modelled as a reduction in contribution to transmission by the resistant parasites of 0-9% [10]. Symptomatic and asymptomatic infections were assumed to have different rates of acquisition of resistance mutations to atovaquone proportional to the relative median parasite biomass for individuals in each group. Coverage with anti-malarials was the same for ACT and A-P wherever their efficacy was compared.

The model was used to answer the following questions for a reduction in proportion infected with, and ideally elimination of, *P. falciparum* malaria in low transmission settings: 1) for MDA: a) what is the relative efficacy of A-P versus ACT?; b) what is the additional impact of adjunctive low dose PQ?; c) what are the optimal timing and coverage?; d) how does the impact of LLIN compare with that of MDA?; and, e) how does the impact of MDA vary with transmission intensity? 2) For treatment of symptomatic patients: what is the relative efficacy of A-P versus ACT in the long-term? 3) What interventions are required to eliminate malaria?

Results

Atovaquone-proguanil versus artemisinin combination therapy for mass drug administration

In the model, A-P and ACT had very similar efficacies in reducing parasite prevalence when used for MDA, although this effect was transient (Table 1). The efficacy of a single round of ACT MDA was slightly less than that of A-P at the same coverage (Figure 2) because 10% of infections were artemisinin resistant at the time of the MDA and because of the causal prophylactic effect of A-P against liver stage parasites [11]. During one round of A-P MDA, *de novo* atovaquone resistance appeared and increased to 8.4% of infections by the end of the MDA and had fallen to 5.2% one year later. Because of this, the efficacy of a second round of MDA with A-P one year after the first was diminished with a subsequent nadir parasite prevalence of 3.9%. With two successive annual rounds of MDA with A-P, the proportion resistant to atovaquone increased further to over 19% (Figure 2C). In contrast, the pre-existing artemisinin




Table 1 The modelled nadir and % reductions in parasite prevalence (% infected with *P. falciparum*) in the year following one (*1) or two (*2) annual rounds of MDA using atovaquone-proguanil or ACT +/- primaquine in western Cambodia

MDA strategy used	Nadir parasite prevalence (%)	% decrease in nadir with MDA
Nil	8.9	
Atovaquone-proguanil*1	4.8	45.6
(Atovaquone-proguanil + primaquine)*1	4.6	48.7
Atovaquone-proguanil*2	3.9	56.2
(Atovaquone-proguanil + primaquine)*2	3.5	60.4
ACT*1	5.1	43.1
(ACT + primaquine)*1	4.7	47.7
ACT*2	4.0	55.4
(ACT + primaquine)*2	3.5	60.9

In the examples shown, the MDA was done at the time of maximum efficacy (1–2 months before nadir parasite prevalence).

resistance increased very little with a round of ACT MDA, thus the efficacy of a second round of ACT MDA was relatively greater with ACT (Figure 2D) than with A-P. An alternative strategy of alternating annual rounds of A-P and ACT MDA for four years, i.e. A-P, ACT, A-P then ACT, resulted in a lower peak in atovaquone resistance of 17% and a nadir parasite prevalence of 2.7%.

A-P, ACT, ACT then A-P resulted in a peak in atovaquone resistance of 15% and nadir parasite prevalence of 2.8%.

Due to the uncertainty in the model parameters determining the *de novo* acquisition of atovaquone resistance, a sensitivity analysis was performed to assess their effect on the peak proportion of infections resistant to atovaquone after one MDA with A-P. Three parameters were varied: para_sym:asym , the relative median parasite burdens in symptomatic *versus* asymptomatic individuals, from 100,000:1 to 1:1 with peak % resistant from 8.4 to 13.8%; $\text{acq}_{\text{rvdvg}}$, the rate of atovaquone resistance arising during treatment with A-P, from 1/1,000 to 1/10 days⁻¹ with peak % resistant from 8.3 to 10.3%; and acq_{rvdv} , the rate of atovaquone resistance arising during treatment with the atovaquone pharmacokinetic tail of A-P, from 1/10 to 1/0.5 days⁻¹ with peak % resistant from 2.3 to 9.9%. Varying all three parameters simultaneously resulted in a range of peak % resistant to atovaquone from 2.1 to 18.8%. Varying the fitness cost of atovaquone resistance (cost_v) from 0 to 9% made minimal difference to the results except that the greater the fitness cost, the faster the rate of decay in proportion of atovaquone-resistant infections following an MDA. With $\text{cost} = 0\%$ there was no decay and proportion resistant remained the same in the years following the MDA.

Adding PQ to one round of MDA with ACT or A-P resulted in virtually the same overall decrease in parasite prevalence with both drug choices. When two rounds of




Figure 2 Effect of MDA on parasite prevalence and antimalarial resistance. Effects of **A** atovaquone-proguanil and **B** ACT for a single round of MDA on the % of the population infected with *P. falciparum* over time and the proportions of infections which are resistant to artemisinin and/or atovaquone. **C** and **D** show the effects of two rounds of MDA one year apart. MDA was at 95% coverage in western Cambodia.

MDA with additional PQ were modelled, the drop in parasite prevalence was slightly greater with ACT than with A-P.

Optimal timing of mass drug administration

The maximal reduction in parasite prevalence was achieved with MDA one to two months before the seasonal nadir in parasite prevalence (Figure 3A). The optimal timing of a second round of MDA to maximize reduction in parasite prevalence was as soon as possible after the first, as long as this was before the seasonal nadir in parasite prevalence i.e. within one to two months of commencing the first round. With this aggressive strategy, a nadir parasite prevalence of 2.9% could be achieved for A-P and 3.0% for ACT with two rounds of MDA. However, with A-P, atovaquone resistance increased more rapidly to almost 24% of infections. If the second round of MDA was after the seasonal nadir, then the optimal time for it was in the next transmission season one to two months before the next seasonal nadir (Figure 3B). Results were similar for A-P and for ACT.

Coverage with mass drug administration

The efficacy of MDA was non-linearly related to population coverage (Figure 4). The relative increase in efficacy decreased with increasing coverage for all MDA regimens modelled.

Bed nets versus mass drug administration

The relative efficacy of introduction of LLINs (assuming 30% reduction in force of infection and half-life of two years) on a single occasion was compared to a single round of MDA (Figure 5). Although the initial effect of reducing parasite prevalence was greater for MDA, the LLINs continued to reduce transmission for longer due to their long half-life and the overall effect was a greater eventual fall in parasite prevalence with LLINs. Parasite

prevalence took longer to return to pre-intervention levels after LLINs than after MDA. Two rounds of MDA with 95% coverage one year apart had a similar magnitude and duration of efficacy to a single distribution of bed nets with 25% population coverage. Of course these benefits of LLINs are critically dependent on their reduction in the force of infection and sustained efficacy (i.e. no insecticide resistance).

Efficacy of mass drug administration in different transmission settings

The modelled efficacy of MDA was non-linearly related to transmission intensity in that in settings with higher baseline parasite prevalence, the efficacy of MDA was relatively lower (Figure 6).

Switching treatment to atovaquone-proguanil

When treatment of symptomatic episodes in the model was switched from ACT to A-P at the same coverage of 72%, atovaquone resistance arose rapidly and spread, resulting in an increase in malaria prevalence in the population within one year of its introduction and complete loss of A-P efficacy (>99% atovaquone resistance) as a treatment within four years (Figure 7).

These results were robust to a sensitivity analysis for parameters determining the rate of acquisition of atovaquone resistance. Variation of acq_{rvdvg} from 1/1,000 to 1/10 days⁻¹ made no noticeable difference to the results. Varying acq_{rvdv} from 1/0.5 to 1/10 days⁻¹, resulted in a small change in the time to >99% atovaquone resistance from four to five years.

Combined strategies

It was only possible to eliminate malaria in the model when multiple strategies were used. High coverages with both ACT and LLIN were essential to achieve elimination whereas MDA was not. The most effective strategy was multiple rounds of MDA with ACT + P, high





Figure 3 Effect of varying the timing of atovaquone-proguanil MDA on nadir parasite prevalence. **A.** Timing of a single round of MDA relative to the nadir in the seasonal baseline. **B.** Varying the time between two episodes of MDA.



coverage with ACT for treatment of symptomatic cases maintained until elimination, and long-lasting insecticide-treated bed nets (Figure 8A). With two rounds of MDA 1 year apart at 95% coverage and LLIN at 80% coverage, elimination was achievable with maintained treatment coverage for symptomatic cases of >86% in under 4 years. Without MDA, >93% treatment coverage was required for elimination. Where A-P was used for MDA and treatment in place of ACT in a combined strategy with LLIN, elimination was not possible due to rapidly spreading atovaquone resistance (Figure 8B).

Discussion

The modelled initial efficacy of A-P and dihydroartemisinin-piperaquine ACT for MDA was similar. However, the rapid acquisition and spread of resistance to atovaquone caused the efficacy of A-P to be compromised within a short timeframe. With each round of MDA, the proportion of infections resistant to atovaquone increased

greatly, resulting in diminishing returns for a strategy of this type. This did not occur with artemisinin resistance, which spread very little during a round of MDA. This is partly because of the relatively mild phenotype of artemisinin resistance providing a relatively smaller survival advantage than for atovaquone and because of the much higher frequency of spontaneous appearance of novel resistance-conferring mutations for atovaquone than is thought to be the case for artemisinin resistance [12,13].

With the introduction of A-P for first-line treatment in the model, atovaquone resistance rapidly appeared and spread through the population, resulting in an increase in malaria prevalence in the population within one year of its introduction and complete loss of efficacy as a treatment in four to five years. This is in agreement with the rapid spread of atovaquone resistance shortly after the switch to A-P introduction in the field in western Cambodia and is additional evidence that A-P should not be used for this purpose.




Figure 5 Efficacy of LLINs versus MDA. In this example, the LLINs were distributed on one occasion to 60% of the population and the MDA was a single round with atovaquone-proguanil with coverage 95%, both in 2014.





Figure 6 Efficacy of MDA in different transmission settings. Nadir % infected following a single round of atovaquone-proguanil MDA in settings of different transmission intensity using baseline % infected with *P. falciparum* as a proxy.




The modelling suggests that use of A-P for MDA is questionable, despite the advantage of avoiding additional artemisinin drug pressure. The modelling predicts that the contribution to spread of artemisinin resistance from ACT MDA is minimal. With repeated rounds of ACT MDA the effect on resistance spread is cumulative, although still small. If A-P were to be used, the proportion of infections resistant to atovaquone rose to around 10% of infections with most parameter combinations, following a single round of MDA. The WHO recommends a change of anti-malarial drug in a national malaria treatment policy if treatment failure proportion is $\geq 10\%$ [14]. This would preclude the use of A-P for treatment or prophylaxis following even a single round of A-P MDA. Additionally, A-P can be much more expensive than ACT, although drug cost is only one component of the programme cost of MDA. A combined strategy, including ACT MDA and LLINs and high coverage with ACT for treatment of symptomatic episodes would be a better option for Cambodia. The modelling suggests that the efficacy and efficiency of the MDA used can be optimized by timing it one to two months before the seasonal nadir in parasite prevalence and employing repeated episodes around one year apart. Two rounds of

MDA in rapid succession before the seasonal nadir in transmission are predicted to be even more effective, but may be difficult to implement in the field. An optimal coverage level is difficult to define but the modelling indicates there is little benefit to be gained from small increases in already high coverage as this tails off in a non-linear fashion. Very high levels of coverage are difficult to attain and incur proportionately higher costs. A compromise between cost and coverage would seem reasonable. Low dose PQ added modestly to the efficacy of MDA with either A-P or ACT and should be considered, particularly in areas threatened by artemisinin resistance and areas attempting elimination [15]. However, achievable coverage may be limited by its side-effect of haemolysis in glucose-6-phosphate dehydrogenase deficient individuals.

Conclusions

For malaria elimination, A-P for MDA or treatment of symptomatic cases should be avoided because of the rapid appearance and spread of atovaquone resistance. A combined strategy of ACT + P MDA, LLINs and high coverage with ACT for treatment of symptomatic episodes would be preferable.



Additional files

Additional file 1: Table S1. Assumptions.

Additional file 2: Table S2. Parameters.

Abbreviations

ACT: Artemisinin combination therapy; A-P: Atovaquone-proguanil; LLINs: Long-lasting insecticide-treated bed nets; MDA: Mass drug administration; PQ: Primaquine.

Competing interests

The authors do not have a commercial or other association that might pose a competing interest.

Authors' contributions

RJM designed the study, created the mathematical model and wrote the report. CN, AMD and LJW wrote the report. NJW designed the study, supervised the work and wrote the report. All authors approved the final version of the manuscript.

Acknowledgements

The authors would like to thank the staff at the Cambodia National Malaria Control Programme who collected the field data used in the preparation of this manuscript and S Lee for kindly allowing us to use her data.

Author details

¹Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. ²Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Old Road, Oxford OX3 7LJ, UK. ³National Centre for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.

Received: 13 May 2014 Accepted: 18 September 2014

Published: 24 September 2014

References

1. Global Partnership to Roll Back Malaria: *Eliminating malaria: learning from the past, looking ahead (in IRIS)*. Geneva: World Health Organization; 2011.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ: **Artemisinin resistance in *Plasmodium falciparum* malaria**. *N Engl J Med* 2009, **361**:455–467.
3. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ier Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F: **Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study**. *Lancet* 2012, **379**:1960–1966.
4. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, Lindegardh N, Tarning J, Imwong M, Jacob CG, Rasmussen C, Perin J, Ringwald P, Nyunt MM: **Reduced susceptibility of *Plasmodium falciparum* to artesunate in southern Myanmar**. *PLoS One* 2013, **8**:e57689.
5. Tran TH, Nguyen TT, Nguyen HP, Boni MF, Ngo VT, Nguyen TN, Le HT, Cao QT, Pham VT, Phung DT, Le TL, Le TD, Merson L, Dolecek C, Stepniewska K, Ringwald P, White NJ, Farrar J, Wolbers M: **In vivo susceptibility of *Plasmodium falciparum* to artesunate in Binh Phuoc Province**. *Vietnam Malar J* 2012, **11**:355.
6. Maude RJ, Pontavornpinoy W, Saralamba S, Aguas R, Yeung S, Dondorp AM, Day NP, White NJ, White LJ: **The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia**. *Malar J* 2009, **8**:31.
7. WHO: *Consideration of mass drug administration for the containment of artemisinin-resistant malaria in the Greater Mekong subregion: report of a consensus meeting, 27–28 September 2010, Geneva, Switzerland*. Geneva: World Health Organization; 2011.
8. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ: **Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand**. *Am J Trop Med Hyg* 1996, **54**:62–66.
9. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S, Dondorp AM, Day NP, White NJ, White LJ: **Optimising strategies for *Plasmodium falciparum* malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance**. *PLoS One* 2012, **7**:e37166.
10. Peters JM, Chen N, Gatton M, Korsinczyk M, Fowler EV, Manzetti S, Saul A, Cheng Q: **Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in *Plasmodium falciparum***. *Antimicrob Agents Chemother* 2002, **46**:2435–2441.
11. Berman JD, Nielsen R, Chulay JD, Dowler M, Kain KC, Kester KE, Williams J, Whelen AC, Shmuklarsky MJ: **Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model**. *Trans R Soc Trop Med Hyg* 2001, **95**:429–432.
12. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Pujalon O, Menard D: **A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria**. *Nature* 2014, **505**:50–55.
13. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, et al: **Multiple populations of artemisinin-resistant *Plasmodium falciparum* in Cambodia**. *Nat Genet* 2013, **45**:648–655.
14. WHO: *Guidelines for the treatment of malaria*. 2nd edition. Geneva: World Health Organization; 2010.
15. WHO: *Single dose Primaquine as a gametocytocide in *Plasmodium falciparum* malaria*. Geneva: World Health Organization; 2012.

doi:10.1186/1475-2875-13-380

Cite this article as: Maude et al.: The diminishing returns of atovaquone-proguanil for elimination of *Plasmodium falciparum* malaria: modelling mass drug administration and treatment. *Malaria Journal* 2014 **13**:380.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

